NCT00773695 2023-01-09
A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer
Hoffmann-La Roche
Phase 2 Completed
Hoffmann-La Roche
GlaxoSmithKline
Hoffmann-La Roche
MedImmune LLC
Evgen Pharma